Unity Biotechnology, Inc.

DB:9U9 Stock Report

Market Cap: €18.8m

Unity Biotechnology Valuation

Is 9U9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9U9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9U9's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9U9's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9U9?

Key metric: As 9U9 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9U9. This is calculated by dividing 9U9's market cap by their current book value.
What is 9U9's PB Ratio?
PB Ratio1.4x
BookUS$14.14m
Market CapUS$19.71m

Price to Book Ratio vs Peers

How does 9U9's PB Ratio compare to its peers?

The above table shows the PB ratio for 9U9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average15.3x
VSC 4SC
44.8xn/a€55.6m
MDG1 Medigene
1.2x-4.1%€23.7m
CNW co.don
1xn/a€6.5m
T5O bioXXmed
14.1xn/a€1.4m
9U9 Unity Biotechnology
1.4x55.2%€19.7m

Price-To-Book vs Peers: 9U9 is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (20x).

Price to Book Ratio vs Industry

How does 9U9's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
9U9 1.4xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 9U9 is good value based on its Price-To-Book Ratio (1.4x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 9U9's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9U9 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9U9's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9U9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.09
€6.38
+487.3%
14.3%€7.29€5.47n/a2
Nov ’25€1.23
€6.38
+420.3%
14.3%€7.29€5.47n/a2
Oct ’25€1.29
€6.38
+393.7%
14.3%€7.29€5.47n/a2
Sep ’25€1.47
€6.38
+333.9%
14.3%€7.29€5.47n/a2
Aug ’25€1.39
€6.42
+362.9%
14.3%€7.34€5.51n/a2
Jul ’25€1.23
€5.55
+350.5%
27.2%€7.40€3.70n/a3
Jun ’25€1.41
€5.55
+293.6%
27.2%€7.40€3.70n/a3
May ’25€1.38
€5.65
+308.8%
27.2%€7.53€3.77n/a3
Apr ’25€1.48
€6.19
+319.2%
37.4%€9.28€3.71n/a3
Mar ’25€1.66
€6.19
+272.5%
37.4%€9.28€3.71n/a3
Feb ’25€1.57
€5.98
+280.7%
33.5%€9.20€3.68n/a4
Jan ’25€1.69
€5.99
+254.4%
33.5%€9.22€3.69n/a4
Dec ’24€1.72
€5.99
+247.6%
33.5%€9.22€3.69n/a4
Nov ’24€1.84
€5.68
+207.9%
47.1%€9.46€1.89€1.234
Oct ’24€2.22
€6.72
+201.9%
40.7%€9.16€1.83€1.296
Sep ’24€2.40
€6.72
+180.0%
40.7%€9.16€1.83€1.476
Aug ’24€2.47
€6.99
+183.1%
43.7%€10.94€1.82€1.396
Jul ’24n/a
€7.03
0%
43.7%€11.00€1.83€1.236
Jun ’24n/a
€7.30
0%
39.3%€11.19€2.80€1.416
May ’24n/a
€6.56
0%
46.0%€10.94€2.73€1.385
Apr ’24n/a
€7.01
0%
37.8%€11.06€4.61€1.485
Mar ’24n/a
€28.86
0%
86.7%€75.95€9.49€1.665
Feb ’24€3.97
€28.86
+627.9%
86.7%€75.95€9.49€1.575
Jan ’24€2.38
€28.86
+1,112.7%
86.7%€75.95€9.49€1.695
Dec ’23€2.27
€26.10
+1,052.2%
92.5%€76.85€9.61€1.726
Nov ’23€2.50
€57.88
+2,215.0%
69.4%€121.49€11.14€1.846

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.3b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.20

7D

2.2%

1Y

88.4%

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%